Diagnostic Imaging and Specific Signs
The radiologist's key task when suspecting an autoimmune process is to identify characteristic radiological patterns. Tomographic imaging methods are the most informative.
Computed tomography (CT) reveals the following specific features:
- Enlargement of the pancreas, giving the organ a "sausage-shaped" appearance (sausage-shaped).
- Delayed, homogeneous (uniform) contrast enhancement.
- Presence of a peripancreatic hypodense capsule-like rim (hypoattenuating rim).
Changes also affect the ductal system. The main pancreatic duct shows irregular narrowing with minimal dilatation (diameter $\le$ 5 mm). Endoscopic retrograde cholangiopancreatography (ERCP) is considered a highly specific method as it clearly visualizes diffuse narrowing of the main duct with irregular margins.
Contrast-enhanced ultrasound (CEUS) is effective in differentiating AIP from cancer: autoimmune lesions typically show isointense contrast enhancement in the arterial phase and hyperintense enhancement in the late phase.
Classification and morphological forms
Autoimmune pancreatitis is generally divided into two main types based on the involvement of other body systems:
- Type 1. Acts as a pancreatic manifestation of systemic IgG4-related disease. Besides the gland itself, other organs are involved:
- Biliary tract (cholangitis develops, strictures of the intrahepatic ducts are visible on MRCP).
- Kidneys (bilateral involvement in the form of multiple hypodense lesions).
- Lymph nodes (mediastinal lymphadenopathy, enlargement of porta hepatis nodes).
- Salivary and lacrimal glands, as well as blood vessels.
- Type 2. Represents an isolated lesion strictly limited to the pancreatic tissue.
Depending on the pattern of the inflammatory process, three morphological forms are distinguished. The most frequent is focal (focal, 33% of cases), which presents the greatest difficulty in differential diagnosis with tumors. Multifocal and diffuse (diffuse, 12%) forms are less common.
Diagnosis and management tactics
A definitive diagnosis is established by combining a typical CT picture with positive blood serological tests. Histological confirmation (biopsy) is not always required—it is indicated only for questionable laboratory results or if the identified mass does not decrease after starting steroid therapy. In unclear cases (with an atypical CT or CEUS picture), the algorithm is supplemented by ERCP.
The prognosis in AIP is fundamentally different from the outcomes of chronic pancreatitis or malignant neoplasms. Administration of steroid therapy leads to significant improvement and often complete resolution of symptoms. Follow-up scans at three months typically show complete disappearance of pancreatic edema (although some residual atrophy may be observed). The main challenge in managing such patients remains frequent relapses after the course of treatment finishes.
The focal form must be carefully differentiated from ductal adenocarcinoma (ductal adenocarcinoma). Unlike the autoimmune process, cancer is characterized by early metastasis (especially to the liver) and invasion into adjacent structures. Using the tumor marker CA 19-9 for reliable differential diagnosis is impractical: due to its low specificity, it does not allow for an accurate distinction between benign autoimmune inflammation and a malignant tumor.
Briefly: answers to topical questions
How does autoimmune pancreatitis differ from ductal adenocarcinoma on contrast-enhanced ultrasound (CEUS)?
On contrast-enhanced ultrasound, lesions of autoimmune pancreatitis have a specific enhancement pattern that distinguishes them from cancer.
| Contrast phase | Autoimmune pancreatitis |
|---|---|
| Arterial phase | Isointense enhancement |
| Late phase | Hyperintense enhancement |
Exact characteristics of ductal adenocarcinoma using this method are not described in the sources, but it is noted that the method is highly effective for the differential diagnosis of these conditions.
What specific serological markers are used to confirm autoimmune pancreatitis?
For the laboratory evaluation of the autoimmune etiology of pancreatitis, the sources indicate the following serological markers:
- Serum IgG4 — its elevation is included in the HISORt criteria; in autoimmune pancreatitis, IgG4 levels can be abnormally elevated, although this feature is not always present.
- Thyroperoxidase antibodies (anti-TPO) — determined during the exclusion of autoimmune etiology.
- Thyroglobulin antibodies (anti-Tg) — also determined as part of the laboratory diagnosis of autoimmune etiology.
In the HISORt system, the serological criterion is an elevation in serum IgG4 levels.
What diagnostic criteria (e.g., HISORt) are used to diagnose autoimmune pancreatitis?
The diagnosis is established using the HISORt criteria system, which includes five groups of features.
- Histological features (Histology) — periductal lymphoplasmacytic infiltrate with obliterating phlebitis and fibrosis, abundance of IgG4-positive cells.
- Imaging findings (Imaging) — diffuse glandular enlargement with delayed rim-like contrast enhancement and irregularity of the main pancreatic duct.
- Serological markers (Serology) — elevated serum IgG4 levels.
- Other organ involvement (Other organ involvement) — biliary strictures, involvement of salivary and lacrimal glands, mediastinal lymphadenopathy, retroperitoneal fibrosis.
- Response to treatment (Response to steroid therapy) — positive effect from prednisolone administration within one month.
Class and exam questions
Is a biopsy always required to confirm autoimmune pancreatitis?
No, a biopsy (histological confirmation) is needed only for questionable laboratory results or if the mass does not regress in response to trial steroid therapy.
How to distinguish AIP from pancreatic cancer on CEUS?
On contrast-enhanced ultrasound, AIP lesions are typically isointense in the arterial phase and become hyperintense in the late phase, which is atypical for ductal adenocarcinoma.
What are the extrapancreatic manifestations of Type 1 AIP?
Type 1 AIP is accompanied by biliary duct involvement (cholangitis), kidney, lymph node, salivary, and lacrimal gland involvement as part of systemic IgG4-related disease.
Will the tumor marker CA 19-9 help distinguish focal AIP from cancer?
No, this marker lacks sufficient sensitivity and specificity, so it is not used for differential diagnosis between benign masses and cancer.
What else to study on this topic
- Ductal adenocarcinoma: growth and metastasis characteristics
- Algorithm for radiological staging of unresectable pancreatic cancer
- Radical pancreatoduodenectomy (Whipple procedure)
- MRCP picture of intrahepatic bile duct strictures
- The role of transabdominal ultrasound as a first-line method
Master the entire topic in the "Diagnostic Radiology" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Autoimmune pancreatitis" and 2,199 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 10 video lessons on the subject
Other topics in the section "Diagnostic Radiology of the Abdominal Organs"
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.